Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients

Recruiting now · Early Phase 1

Conditions studied: Duchenne Muscular Dystrophy (DMD)

In brief

The primary objective of this study is to evaluate the safety and tolerability of SPOT-03 administered by intravenous (IV) infusion to DMD patients. In addition, this study will preliminarily investigate the changes in dystrophin nucleic acid concentration, dystrophin protein expression and engraftment, anti-dystrophin antibodies and cytokine profiles, as well as fat tissue mas and lean tissue mass following SPOT-03 administrations.

Key facts

Study ID

NCT07188012

Run by

Shanghai Siponuoyin Biotechnology Co Ltd

People needed

9

Starts

2025-08-06

Expected to finish

2026-12-01

Last updated by the study team

2026-05-07

Who can join

Age: 2 and older, up to 7. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• According to the requirements of the region/country and/or IRB/IEC, the patient and/or legal guardian have signed a written informed consent form and are aware of all relevant study content.
• Boys aged ≥ 2 years to < 8 years and capable of walking independently for at least 10 meters.
• The medical history includes clinical diagnosis of DMD and confirmed Duchenne mutations using validated genetic testing (MLPA and whole genome sequencing).
• Able to tolerate muscle biopsy under anesthesia and have no contraindications to biopsy.
• Heart, liver, lung, and kidney functions are sufficient:
• The left ventricular ejection fraction (LVEF) should be ≥ 50%;
• Forced vital capacity (FVC) > 50% of the expected value, and do not require nighttime ventilation;
• Patient's glomerular filtration rate (GFR)>30 mL/min/1.73 m2

You may not qualify if…

• Complications other than DMD that may cause muscle weakness and/or motor dysfunction.
• There are severe intellectual disabilities (such as severe autism, severe cognitive impairment, and severe behavioral disorders) that, according to the investigator's judgment, can affect the study.
• Hospitalization for respiratory failure within 8 weeks prior to screening.
• Asthma or underlying lung diseases that are poorly controlled, such as bronchitis, bronchiectasis, emphysema, or recurrent infectious pneumonia that investigator believes may affect respiratory function.
• Severe uncontrolled heart failure (NYHA III-IV), including any of the following conditions：
• Intravenous administration of diuretics or positive inotropic drugs is required within 8 weeks prior to screening.
• Hospitalization due to worsening heart failure or arrhythmia within 8 weeks prior to screening.
• Abnormal laboratory values considered clinically significant:
• GGT > 3 × upper limit of normal
• Bilirubin ≥ 3.0 mg/dL
• Creatinine ≥ 1.8 mg/dL
• Hemoglobin < 8 or > 18 g/dL
• White blood cell count > 18,500/μL
• Arrhythmias that require anti-arrhythmic treatment.
• Subjects who are undergoing immunosuppressive therapy.
• Has used other gene therapy, investigational drugs, or any treatment aimed at increasing dystrophin expression.
• Subjects with a history of major surgeries within 12 weeks prior to the initial infusion or planning to undergo major surgeries (such as scoliosis surgery) during this study.
• Subjects who are allergic to investigational products or local aesthetic drugs or have a history of severe allergies or genetic allergic reactions.
• Within 6 months prior to the initial infusion, the subjects are exposed to another investigational drug or have participated in an intervention clinical trial.
• Subjects with positive hepatitis B core antibody or hepatitis C antibody or HIV antibody during screening.
• Investigator believes that the presence of any other serious diseases, medical conditions, or chronic drug treatment needs can pose unnecessary risks to gene transfer.

Where it is running

• Shanghai Children's Medical Center — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.